Literature DB >> 29250193

Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinoma.

Xiao-Peng Zhang1, Zhi-Juan Hu2, Ai-Hong Meng3, Guo-Chen Duan1, Qing-Tao Zhao1, Jing Yang4.   

Abstract

Previous studies have revealed that carcinoma-associated fibroblasts communicate microenvironment-derived signals through chemokine/chemokine receptor interaction, resulting in carcinogenesis. C-C motif chemokine ligand 20 (CCL20)/C-C motif chemokine receptor 6 (CCR6) interactions are involved in the pathogenesis of colonic malignancies. The present study aimed to characterize the roles of CCL20/CCR6 and the extracellular signal-regulated kinase (ERK) signaling pathway in lung adenocarcinoma growth. Lung adenocarcinoma samples obtained at surgery were assessed for the expression, tissue localization and production of CCL20/CCR6. In addition, colony formation, ERK signaling and chemokine production were measured to assess the responsiveness of the A549 cell line to CCL20 stimulation. CCL20 and CCR6 were found to be highly expressed in the majority of samples in the recurrence group (76 and 66%, respectively). The staining indexes of CCL20 and CCR6 in the recurrence group were 149.3 and 134.4, respectively, which were significantly higher than those in the non-recurrence group (57.2 and 58.0, respectively); the protein and mRNA expression levels determined by western blot and reverse transcription-quantitative polymerase chain reaction were also found to be high in the recurrence group For A549 cells, the colony-forming capacity was increased by CCL20 stimulation, and this effect was dependent in part on ERK phosphorylation. Collectively, the findings suggest that CCR6 and CCL20 may serve a role in lung adenocarcinoma, leading to proliferation and migration via autocrine or paracrine mechanisms. The disruption of CCL20/CCR6 interactions may be a promising strategy for the treatment of cancer.

Entities:  

Keywords:  C-C motif chemokine ligand 20; C-C motif chemokine receptor 6; extracellular signal-regulated kinase; lung adenocarcinoma; recurrence

Year:  2017        PMID: 29250193      PMCID: PMC5727607          DOI: 10.3892/ol.2017.7253

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer.

Authors:  J Kleeff; T Kusama; D L Rossi; T Ishiwata; H Maruyama; H Friess; M W Büchler; A Zlotnik; M Korc
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

3.  Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer.

Authors:  Pirus Ghadjar; Sarah Ellen Coupland; Il-Kang Na; Michel Noutsias; Anne Letsch; Andrea Stroux; Sandra Bauer; Heinz J Buhr; Eckhard Thiel; Carmen Scheibenbogen; Ulrich Keilholz
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

Review 4.  Chemokines and their role in tumor growth and metastasis.

Authors:  J M Wang; X Deng; W Gong; S Su
Journal:  J Immunol Methods       Date:  1998-11-01       Impact factor: 2.303

5.  The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways.

Authors:  R K Ganju; S A Brubaker; J Meyer; P Dutt; Y Yang; S Qin; W Newman; J E Groopman
Journal:  J Biol Chem       Date:  1998-09-04       Impact factor: 5.157

6.  Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt.

Authors:  Simone Barbero; Rudy Bonavia; Adriana Bajetto; Carola Porcile; Paolo Pirani; Jean Louis Ravetti; Gian Luigi Zona; Renato Spaziante; Tullio Florio; Gennaro Schettini
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

Review 7.  Chemokines in cancer.

Authors:  Alain P Vicari; Christophe Caux
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

8.  Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease.

Authors:  Ingel K Demedts; Ken R Bracke; Geert Van Pottelberge; Dries Testelmans; Geert M Verleden; Frank E Vermassen; Guy F Joos; Guy G Brusselle
Journal:  Am J Respir Crit Care Med       Date:  2007-03-01       Impact factor: 21.405

Review 9.  The CC chemokine CCL20 and its receptor CCR6.

Authors:  Evemie Schutyser; Sofie Struyf; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2003-10       Impact factor: 7.638

Review 10.  CC-chemokine receptors in chronic obstructive pulmonary disease.

Authors:  Ken R Bracke; Ingel K Demedts; Guy F Joos; Guy G Brusselle
Journal:  Inflamm Allergy Drug Targets       Date:  2007-06
View more
  18 in total

1.  In vitro chemokine (C-C motif) receptor 6-dependent non-inflammatory chemotaxis during spermatogenesis.

Authors:  Ruiying Diao; Xueyong Cai; Lu Liu; Lihua Yang; YongGang Duan; Zhiming Cai; Yaoting Gui; Lisha Mou
Journal:  Biol Res       Date:  2018-05-22       Impact factor: 5.612

2.  Sputum Detection of Predisposing Genetic Mutations in Women with Pulmonary Nontuberculous Mycobacterial Disease.

Authors:  Julie V Philley; Kate L Hertweck; Anbarasu Kannan; Barbara A Brown-Elliott; Richard J Wallace; Anna Kurdowska; Harrison Ndetan; Karan P Singh; Edmund J Miller; David E Griffith; Santanu Dasgupta
Journal:  Sci Rep       Date:  2018-07-27       Impact factor: 4.379

Review 3.  The CCL20-CCR6 Axis in Cancer Progression.

Authors:  Suguru Kadomoto; Kouji Izumi; Atsushi Mizokami
Journal:  Int J Mol Sci       Date:  2020-07-22       Impact factor: 5.923

4.  Transcriptomic studies revealed pathophysiological impact of COVID-19 to predominant health conditions.

Authors:  Zulkar Nain; Shital K Barman; Md Moinuddin Sheam; Shifath Bin Syed; Abdus Samad; Julian M W Quinn; Mohammad Minnatul Karim; Mahbubul Kabir Himel; Rajib Kanti Roy; Mohammad Ali Moni; Sudhangshu Kumar Biswas
Journal:  Brief Bioinform       Date:  2021-06-02       Impact factor: 11.622

Review 5.  Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer.

Authors:  Ranmali Ranasinghe; Rajaraman Eri
Journal:  Medicina (Kaunas)       Date:  2018-11-16       Impact factor: 2.430

6.  lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling.

Authors:  Wei Wei; Xiaoliang Zhao; Jianquan Zhu; Lianmin Zhang; Yulong Chen; Bin Zhang; Yue Li; Meng Wang; Zhenfa Zhang; Changli Wang
Journal:  Oncol Rep       Date:  2019-09-05       Impact factor: 3.906

7.  Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis.

Authors:  Suguru Kadomoto; Kouji Izumi; Kaoru Hiratsuka; Taito Nakano; Renato Naito; Tomoyuki Makino; Hiroaki Iwamoto; Hiroshi Yaegashi; Kazuyoshi Shigehara; Yoshifumi Kadono; Hiroki Nakata; Yohei Saito; Kyoko Nakagawa-Goto; Atsushi Mizokami
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

8.  Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer.

Authors:  Min Chen; Juan Su; Chunmei Feng; Ying Liu; Li Zhao; Yongjie Tian
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

9.  Tongue Cancer Cell-Derived CCL20 Induced by Interaction With Macrophages Promotes CD163 Expression on Macrophages.

Authors:  Manabu Shigeoka; Yu-Ichiro Koma; Takayuki Kodama; Mari Nishio; Masaya Akashi; Hiroshi Yokozaki
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

10.  Integration of gene profile to explore the hub genes of lung adenocarcinoma: A quasi-experimental study.

Authors:  Peiyan Hua; Yan Zhang; Chengyan Jin; Guangxin Zhang; Bin Wang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.